TY - T1的长期结果和安全的长期bedaquiline治疗耐多药结核病JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01799 -2016欧元六世- 49 - 3 SP - 1601799 AU -洛伦佐Guglielmetti AU -玛丽Jaspard AU -达勒杜AU -玛丽Lachatre盟Dhiba Marigot-Outtandy AU -克里斯汀·伯纳德盟尼古拉斯Veziris盟——杰罗姆·罗伯特盟Yazdan Yazdanpanah AU -埃里克Caumes盟马蒂尔德Frechet-Jachym Y1 - 2017/03/01 UR - //www.qdcxjkg.com/content/49/3/1601799.abstract N2 bedaquiline最近批准的药物治疗耐多药结核病(mdr - tb),建议24周的持续时间。患者有稀缺的数据在这以外的药物临床试验。所有从1月1日开始治疗的耐多药结核病患者,2011年到2013年12月31日,≥30天bedaquiline被包含在一个多中心观察队列。在45个耐多药结核病患者中,53%怀有隔离耐氟喹诺酮类原料药和二线注射剂和38%怀有隔离抵抗这些药物类之一。bedaquiline治疗持续时间中位数为361天,33名患者(73%)接受了(在190天)bedaquiline延长治疗。总的来说,36例(80%)有有利的结果,五是失访,三个死了,和一个失败,获得bedaquiline阻力。没有复发的病例报道。严重和严重不良事件记录在60%和18%的病人,分别。Fridericia-corrected QT间隔的值(QTcF)在500 ms在11%的病人记录,但是心律失常和心脏副作用症状发生。Bedaquiline QTcF延长后停止在三个病人。 No significant differences in outcomes or adverse events rates were observed between patients receiving standard and prolonged bedaquiline treatment.Bedaquiline-containing regimens achieved favourable outcomes in a large proportion of patients. Prolonged bedaquiline treatment was overall well tolerated in this cohort.Treatment regimens including prolonged bedaquiline use are effective and overall well tolerated in MDR-TB patients http://ow.ly/vhtl305CYJj ER -